Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BIOLASE Inc    

BIOLASE INC
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

BIOLASE Inc : BIOLASE Expects to Report Positive Cash Flow From Operations for Q4 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/22/2013 | 02:44pm CEST
BIOLASE Expects to Continue to Generate Positive Cash Flow From Operations for 2013 Overall

IRVINE, CA -- (MARKETWIRE) -- 01/22/13 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, announced today that based on preliminary unaudited financial results, the Company expects to report that it generated positive cash flow from operations for Q4 2012.

"We are pleased with our preliminary unaudited financial results for Q4 2012. It is rewarding to see that our restructuring efforts over the past two years have enabled us to turn the Company around and that we are making significant progress toward achieving our financial goals," said Federico Pignatelli, Chairman and CEO. "The trends we are seeing in the adoption of dental lasers also give us confidence in achieving continued double-digit growth of our core dental franchise. Based on our current plans, we expect the Company will continue to generate positive cash flow from operations for the overall year ending December 31, 2013."

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biological treatment and clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment and CAD/CAM systems. BIOLASE has sold more than 21,000 lasers.

Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

For further information, please contact:
Lisa Wilson
In-Site Communications, Inc.
212-759-3929


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOLASE INC
05/17BIOLASE : and Los Angeles Chargers Partner to Bring Advanced Dental Care to Chil..
AQ
05/17BIOLASE : Announces 1-for-5 Reverse Stock Split Common Stock Will Begin Trading ..
AQ
05/11BIOLASE, INC. (NASDAQ : BIOL) Files An 8-K Amendments to Articles of Incorporati..
AQ
05/11BIOLASE, INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
05/10BIOLASE, INC : Change in Directors or Principal Officers, Submission of Matters ..
AQ
05/10BIOLASE : Announces 1-for-5 Reverse Stock Split Common Stock Will Begin Trading ..
PU
05/09BIOLASE : and Los Angeles Chargers Partner to Bring Advanced Dental Care to Chil..
PU
05/04BIOLASE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
05/03BIOLASE : Patent Application Titled "Dental System and Method" Published Online ..
AQ
05/03BIOLASE : Change in Directors or Principal Officers (form 8-K/A)
AQ
More news
News from SeekingAlpha
05/02Biolase's (BIOL) CEO John Beaver on Q1 2018 Results - Earnings Call Transcrip.. 
05/02Biolase beats by $0.01, misses on revenue 
04/11BIOLASE to explore strategic alternatives, CEO resigns 
03/14Biolase's (BIOL) CEO Harold Flynn on Q4 2017 Results - Earnings Call Transcri.. 
03/14Biolase EPS in-line, misses on revenue 
Financials ($)
Sales 2018 47,8 M
EBIT 2018 -18,2 M
Net income 2018 -16,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0,52x
Capi. / Sales 2019 0,49x
Capitalization 24,8 M
Chart BIOLASE INC
Duration : Period :
BIOLASE Inc Technical Analysis Chart | US0909111082 | 4-Traders
Technical analysis trends BIOLASE INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 2
Average target price 4,50 $
Spread / Average Target 285%
EPS Revisions
Managers
NameTitle
John R. Beaver CEO, CFO & Principal Accounting Officer
Jonathan T. Lord Chairman
Richard R. Whipp Vice President-Operations
Dmitri Boutoussov Vice President-Research & Development
James R. Talevich Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOLASE INC-27.35%25
THERMO FISHER SCIENTIFIC13.20%86 475
DANAHER CORPORATION10.15%70 730
INTUITIVE SURGICAL26.97%51 979
BOSTON SCIENTIFIC CORPORATION23.64%42 015
ROYAL PHILIPS16.04%40 566